Lighting Science (LSCG) 10-Q 13 Nov 15 2015 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 10, 2015
Entity Registrant Name	LIGHTING SCIENCE GROUP CORP
Entity Central Index Key	866,970
Trading Symbol	lscg
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		211,756,727
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Series H Preferred Stock [Member]
Current liabilities:
Series H Redeemable Convertible Preferred Stock, $.001 par value, authorized 135,000 shares, 113,609 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively	$ 227,220,149	$ 227,220,149
Series I Preferred Stock [Member]
Current liabilities:
Series H Redeemable Convertible Preferred Stock, $.001 par value, authorized 135,000 shares, 113,609 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively	124,736,627	124,736,627
Series J Preferred Stock [Member]
Current liabilities:
Series H Redeemable Convertible Preferred Stock, $.001 par value, authorized 135,000 shares, 113,609 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively	160,124,000	116,950,000
Cash and cash equivalents	574,111	1,609,297
Restricted cash	3,000,000	3,000,000
Accounts receivable, net	13,131,606	10,417,985
Inventories	27,360,094	22,726,162
Prepaid expenses	955,644	2,936,837
Other current assets	2,345,374	1,610,544
Total current assets	47,366,829	42,300,825
Property and equipment, net (includes accumulated depreciation of $11.7 million and $10.3 million as of September 30, 2015 and December 31, 2014, respectively)	1,257,851	2,650,115
Intangible assets, net	2,805,375	2,572,479
Pegasus Commitment	286,400	720,000
Debt issuance costs, less current portion	2,148,826	3,230,446
Other long-term assets	132,598	118,467
Total assets	53,997,879	51,592,332
FCC ABL, revolving line of credit	6,960,340	6,368,793
Current portion of long-term debt	52,755	58,574
Accounts payable	15,340,305	19,364,552
Provision for losses on non-cancelable purchase commitments	31,710	540,227
Accrued expenses	7,993,916	9,924,316
Total current liabilities	30,379,026	36,256,462
Medley Term Loan	$ 28,871,320	27,813,061
Long-term debt, less current portion		35,272
Liabilities under derivative contracts	$ 6,703,054	5,636,944
Total other liabilities	35,574,374	33,485,277
Total liabilities	65,953,400	69,741,739
Series H Redeemable Convertible Preferred Stock, $.001 par value, authorized 135,000 shares, 113,609 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively	$ 512,080,776	$ 468,906,776
Commitments and contingencies
Stockholders' deficit:
Preferred stock, $.001 par value, authorized 25,000,000 shares, 113,609 shares of Series H, 62,365 shares of Series I and 80,62 shares of Series J issued and outstanding as of September 30, 2015 and 113,609 shares of Series H, 62,365 shares of Series I and 58,475 shares of Series J issued and outstanding as of December 31, 2014
Common stock, $.001 par value, authorized 975,000,000 shares, 214,326,722 and 212,452,636 shares issued as of September 30, 2015 and December 31, 2014, respectively	$ 214,327	$ 212,453
Additional paid-in capital	298,612,012	320,175,440
Accumulated deficit	(816,104,632)	(800,328,573)
Accumulated other comprehensive loss	(3,000,504)	(3,358,003)
Treasury stock, 2,505,000 shares as of September 30, 2015 and December 31, 2014 , at cost	(3,757,500)	(3,757,500)
Total stockholders’ deficit	(524,036,297)	(487,056,183)
Total liabilities and stockholders’ deficit	$ 53,997,879	$ 51,592,332

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Series H Preferred Stock [Member]
Redeemable Convertible Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Redeemable Convertible Preferred Stock, Authorized Shares (in shares)	135,000	135,000
Redeemable Convertible Preferred Stock, Shares Issued (in shares)	113,609	113,609
Redeemable Convertible Preferred Stock, Shares Outstanding (in shares)	113,609	113,609
Series I Preferred Stock [Member]
Redeemable Convertible Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Redeemable Convertible Preferred Stock, Authorized Shares (in shares)	90,000	90,000
Redeemable Convertible Preferred Stock, Shares Issued (in shares)	62,365	62,365
Redeemable Convertible Preferred Stock, Shares Outstanding (in shares)	62,365	62,365
Series J Preferred Stock [Member]
Redeemable Convertible Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Redeemable Convertible Preferred Stock, Authorized Shares (in shares)	85,100	85,100
Redeemable Convertible Preferred Stock, Shares Issued (in shares)	80,062	58,475
Redeemable Convertible Preferred Stock, Shares Outstanding (in shares)	80,062	58,475
Accumulated depreciation	$ 11,700,000	$ 10,300,000
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized (in shares)	975,000,000	975,000,000
Common Stock, Shares Issued (in shares)	214,326,722	212,452,636
Treasury Stock, Shares (in shares)	2,505,000	2,505,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Parent [Member]
Basic and diluted net loss per weighted average common share (in dollars per share)	$ (0.04)	$ (0.04)	$ (0.12)	$ (0.35)
Basic and diluted weighted average number of common shares outstanding (in shares)	303,817,578	255,194,735	296,699,120	220,629,709
Noncontrolling Interest [Member]
Basic and diluted net loss per weighted average common share (in dollars per share)	$ (0.04)	$ (0.04)	$ (0.12)	$ (0.36)
Basic and diluted weighted average number of common shares outstanding (in shares)	98,997,606	63,038,781	98,591,636	53,029,108
Revenue	$ 19,587,399	$ 23,089,356	$ 62,229,307	$ 68,843,061
Cost of goods sold (exclusive of depreciation shown below)	14,363,734	20,166,431	50,658,859	62,705,900
Gross profit	5,223,665	2,922,925	11,570,448	6,137,161
Selling, distribution and administrative (includes related party expenses of $0 and $11,000 for the three months ended September 30, 2015 and 2014; $0 and $880,000 for the nine months ended September 30, 2015 and 2014, respectively	3,902,694	7,888,383	15,894,335	26,586,501
Research and development	$ 598,988	1,099,010	2,833,298	4,177,616
Restructuring expense		2,466,505	297,770	2,672,350
Depreciation and amortization	$ 474,717	615,879	1,468,860	2,692,202
Total operating expenses	4,976,399	12,069,777	20,494,263	36,128,669
Income (loss) from operations	247,266	(9,146,852)	(8,923,815)	(29,991,508)
Interest income	2	2,839	1,165	3,475
Interest expense	(1,583,501)	(1,494,926)	(4,713,332)	(4,779,245)
Related party interest expense	(138,300)	(138,300)	(338,067)	(338,067)
Decrease in fair value of liabilities under derivative contracts	2,005,783	8,813,540	(1,499,710)	(18,682,848)
Other (expense) income, net	(247,463)	(138,877)	(287,857)	(36,862)
Total other income	36,521	7,044,276	(6,837,801)	(23,833,547)
Income (loss) before income tax expense	283,787	$ (2,102,576)	(15,761,616)	$ (53,825,055)
Income tax expense	14,443		14,443
Net income (loss)	269,344	$ (2,102,576)	(15,776,059)	$ (53,825,055)
Foreign currency translation adjustment	241,736	60,574	357,499	211,279
Comprehensive income (loss)	$ 511,080	$ (2,042,002)	$ (15,418,560)	$ (53,613,776)

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Related party expenses	$ 0	$ 11,000	$ 0	$ 880,000

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Stockholders' Deficit (Unaudited) - 9 months ended Sep. 30, 2015 - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2014	212,452,636
Balance at Dec. 31, 2014	$ 212,453	$ 320,175,440	$ (800,328,573)	$ (3,358,003)	$ (3,757,500)	$ (487,056,183)
Issuance of restricted stock for directors' compensation (in shares)	1,934,515
Issuance of restricted stock for directors' compensation	$ 1,935	255,907				257,842
Stock based compensation expense (in shares)	(66,000)
Stock based compensation expense	$ (66)	915,921				915,855
Stock issued under equity compensation plans (in shares)	5,571
Stock issued under equity compensation plans	$ 5	842				847
Issuance of Series J Warrants		8,144,213				8,144,213
Deemed dividends on Series J Redeemable Convertible Preferred Stock		$ (30,880,311)				(30,880,311)
Net loss			$ (15,776,059)			(15,776,059)
Foreign currency translation adjustment				$ 357,499		357,499
Balance (in shares) at Sep. 30, 2015	214,326,722
Balance at Sep. 30, 2015	$ 214,327	$ 298,612,012	$ (816,104,632)	$ (3,000,504)	$ (3,757,500)	$ (524,036,297)

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Series J Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of Series J Redeemable Convertible Preferred Securities	$ 21,538,000	$ 25,475,000
Non-cash investing and financing activities:
Deemed dividends	(30,880,311)	$ (42,268,257)
Receivable for issuance of Series J Redeemable Convertible Preferred Stock	$ 49,000
Series J Warrants [Member]
Non-cash investing and financing activities:
Reclass of Series J Warrants from liabilities to equity		$ 37,646,300
Issuance of Series J Warrants	$ 8,144,213	3,849,742
THD Warrant [Member]
Non-cash investing and financing activities:
Reclass of THD Warrant from equity to liabilities		(74,576)
Pegasus Guaranty Warrants [Member]
Non-cash investing and financing activities:
Deemed dividends		(570,574)
Fair value of Pegasus Guaranty included in debt issuance costs		(2,766,000)
Net loss	$ (15,776,059)	(53,825,055)
Depreciation and amortization	$ 1,468,860	2,692,202
Impairment of plant and equipment		41,555
Allocated Share-based Compensation Expense	$ 257,842	412,451
Stock based compensation expense	$ 915,855	1,901,285
Non-cash sales incentive		99,801
Allowance for doubtful accounts receivable	$ 83,105	25,672
Write-down of inventory	853,160	$ 1,491,365
Provision for losses on non-cancelable purchase commitments	115,926
Increase in fair value of derivative contracts	1,499,710	$ 18,682,848
Amortization of debt issuance costs	1,131,106	1,299,931
Medley discount accretion	584,304	473,935
Interest accrued on Medley Term Loan	473,955	381,611
Loss on disposal of assets	30,793	639,490
Accounts receivable	(2,718,024)	(5,520,513)
Inventories	(6,102,438)	(5,434,495)
Prepaid expenses	1,981,498	(1,287,842)
Other current and long-term assets	(459,698)	139,753
Accounts payable	(4,003,021)	1,056,734
Accrued expenses and other liabilities	(1,892,901)	1,790,940
Net cash used in operating activities	(21,556,027)	(34,938,332)
Purchases of property and equipment	(15,042)	(420,116)
Capitalized patents	(325,739)	(687,079)
Proceeds from sale of property and equipment	500	383,159
Net cash used in investing activities	(340,281)	(724,036)
Net proceeds (payments) from draws on lines of credit and other short-term borrowings	$ 591,547	(28,056,176)
Proceeds from long-term borrowings		29,775,000
Payment of short and long-term debt	$ (41,091)	(4,050)
Debt issuance costs	$ (338,749)	(3,210,206)
Decrease in restricted cash related to line of credit		2,000,000
Proceeds from issuance of common stock under equity compensation plans	$ 847	5,462
Fees incurred on issuance of preferred stock	(1,149,098)	(437,776)
Net cash provided by financing activities	20,601,456	25,547,254
Effect of exchange rate changes on cash	259,666	157,732
Net decrease in cash	(1,035,186)	(9,957,382)
Cash and cash equivalents balance at beginning of period	1,609,297	11,195,412
Cash and cash equivalents balance at end of period	574,111	1,238,030
Interest paid during the period	$ 3,824,787	$ 3,753,932

Note 1 - Description of Busines

Note 1 - Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Description of Business and Basis of Presentation Overview Lighting Science Group Corporation (the “Company”) was incorporated in Delaware in 1988 and designs, develops, manufactures and markets general illumination products that use light emitting diodes (“LEDs”) as their exclusive light source. The Company’s product portfolio includes LED-based retrofit lamps (replacement bulbs) used in existing light fixtures as well as purpose built LED-based luminaires (light fixtures). The Company’s lamps and luminaires are used for many common indoor and outdoor residential, commercial, industrial and public infrastructure lighting applications. The Company assembles and manufactures products primarily through its contract manufacturers in Asia. Basis of Financial Statement Presentation The accompanying unaudited condensed consolidated financial statements are presented pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) in accordance with the disclosure requirements for the quarterly report on Form 10-Q and therefore do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) necessary to fairly state the results for the interim periods presented. The condensed consolidated balance sheet as of December 31, 2014 is derived from the Company’s audited financial statements. Operating results for the three and nine months ended September 30, 2015 are not necessarily indicative of the results of the Company that may be expected for the year ending December 31, 2015. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2014 and notes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on March 31, 2015. The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in the accompanying condensed consolidated financial statements.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. The Company’s actual results could differ from these estimates. Restricted Cash As of September 30, 2015 and December 31, 2014, as required by the Company’s five-year term loan (as amended from time to time, the “Medley Term Loan”) with Medley Capital Corporation (“Medley”), the Company maintained a minimum restricted cash balance of $3.0 million to collateralize the Medley Term Loan. Changes in the restricted cash balance are reflected as a financing activity in the consolidated statement of cash flows. Accounts Receivable The Company records accounts receivable at the invoiced amount when its products are shipped to customers or when specific milestone billing requirements are completed. The Company’s accounts receivable balance is recorded net of allowances for amounts not expected to be collected from customers. This allowance for doubtful accounts is the Company’s best estimate of probable credit losses in the Company’s existing accounts receivable. Estimates used in determining the allowance for doubtful accounts are based on historical collection experience, age of receivables and known collectability issues. The Company writes off accounts receivable when it becomes apparent, based on age or customer circumstances, that such amounts will not be collected. The Company reviews its allowance for doubtful accounts on a quarterly basis. Recovery of bad debt amounts previously written off is recorded as a reduction of bad debt expense in the period the payment is collected. Generally, the Company does not require collateral for its accounts receivable and does not regularly charge interest on past due amounts. As of September 30, 2015 and December 31, 2014, the Company’s accounts receivable were reflected net of an allowance for doubtful accounts of $483 ,000 and $408,000, respectively. As of September 30, 2015 and December 31, 2014, $6.6 million and $5.4 million, respectively, of eligible accounts receivable were pledged as collateral for the three-year asset based revolving credit facility (as amended from time to time, the “FCC ABL”) entered into on April 25, 2014 with FCC, LLC d/b/a First Capital (“First Capital”). First Capital sold the FCC ABL to ACF Finco I LP (“Ares”) in May 2015, and the FCC ABL is hereinafter referred to as the “Ares ABL.” Revenue Recognition The Company records revenue when its products are shipped and title passes to customers. When sales of products are subject to certain customer acceptance terms, revenue from such sales is recognized once those terms have been met. The Company also provides its customers with limited rights of return for non-conforming shipments or product warranty claims. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014‑09”). ASU 2014-09 seeks to clarify the principles for recognizing revenue and to develop a common revenue standard for GAAP and International Financial Reporting Standards. ASU 2014‑09 initially was effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. However, at its July 9, 2015 meeting, the FASB agreed to defer by one year the mandatory effective date of this standard, but will also provide the option to adopt it as of the original effective date. The Company is currently evaluating the impact of adopting ASU 2014‑09, but the standard is not expected to have a significant effect on its consolidated financial statements. Product Warranties The Company generally provides a five-year limited warranty covering defective materials and workmanship of its products. Such warranty may require the Company to repair, replace or reimburse the purchaser for the purchase price of the product. The estimated costs related to warranties are accrued at the time products are sold based on various factors, including the Company’s stated warranty policies and practices, the historical frequency of claims and the cost to repair or replace its products under warranty. The warranty provision is included in accrued expenses on the condensed consolidated balance sheet. Changes in the warranty provision for the nine months ended September 30, 2015 were as follows: Warranty provision as of December 31, 2014 $ 4,789,470 Additions to provision 1,422,333 Less warranty costs (2,518,190 ) Warranty provision as of September 30, 2015 $ 3,693,613 Fair Value Measurements The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: • Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. • Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. • Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. Fair Value of Financial Instruments Cash and cash equivalents, accounts receivable, accounts payable, amounts due under lines of credit and other short term borrowings, accrued expenses and the note payable are carried at amounts that approximate their fair value due to the short-term maturity of these instruments and/or variable, market driven interest rates. The liabilities under derivative contracts, which represent warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), were initially recorded at fair value and subsequently reflected at their fair value at the end of each reporting period. The fair value of the warrant issued to The Home Depot, Inc. (the “THD Warrant”) in January 2011 is determined using the Monte Carlo valuation method and will be adjusted at each reporting date until the underlying shares have been earned for each year. Such adjustments will be recorded as a reduction in the related revenue (sales incentive) from The Home Depot, Inc. (“The Home Depot”). Once a portion of the THD Warrant vests it is recorded at its fair value at the end of each subsequent reporting period. Reclassification Certain prior period amounts in the accompanying consolidated financial statements have been reclassified to conform to the current year presentation. These reclassifications had no effect on previously reported net loss or stockholders’ deficit.

Note 3 - Liquidity and Capital

Note 3 - Liquidity and Capital Resources	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Liquidity and Capital Resources [Text Block]	Note 3. Liquidity and Capital Resources As shown in the condensed consolidated financial statements, the Company has experienced significant historical net losses as well as negative cash flows from operations since its inception, resulting in an accumulated deficit of $816.1 million and stockholders’ deficit of $524.0 million as of September 30, 2015. As of September 30, 2015, the Company had cash and cash equivalents of $574 ,000 and an additional $3.0 million in restricted cash subject to a cash collateral dominion agreement pursuant to the Medley Term Loan. The Company’s cash expenditures primarily relate to procurement of inventory, payment of salaries, employee benefits and other operating costs. The Company’s primary sources of liquidity have historically been borrowings from Ares under the Ares ABL, from Medley under the Medley Term Loan and from other previous lenders, as well as sales of Common Stock and Preferred Stock (as defined below) to, and short-term loans from, affiliates of Pegasus Capital Advisors, L.P. (“Pegasus Capital”), including Pegasus Partners IV, L.P. (“Pegasus IV”), LSGC Holdings LLC (“LSGC Holdings”), LSGC Holdings II LLC (“Holdings II”), LSGC Holdings III LLC (“Holdings III”) and PCA LSG Holdings, LLC (“PCA Holdings” and collectively with Pegasus Capital, Pegasus IV, LSGC Holdings, Holdings II, Holdings III and their affiliates, “Pegasus”). Pegasus is the Company’s controlling stockholder. The Company obtained the five-year , $30.5 million Medley Term Loan from Medley on February 19, 2014, pursuant to a Term Loan Agreement (as amended from time to time the “Medley Loan Agreement”). Pursuant to the Medley Loan Agreement, the Company is required to achieve a minimum quarterly fixed charge coverage ratio for the preceding 12-month period and to maintain certain minimum EBITDA levels. In connection with the Medley Term Loan, the Company issued a warrant to purchase 5,000,000 shares of Common Stock to each of Medley and Medley Opportunity Fund II LP (the “Medley Warrants”). The Company also obtained a three-year revolving credit facility with a maximum line amount of $22.5 million from Ares on April 25, 2014, pursuant to the terms of a Loan and Security Agreement (as amended from time to time, the “Ares ABL Agreement”). As of September 30, 2015, the Company had $7.0 million in borrowings outstanding under the Ares ABL Agreement and additional borrowing capacity of $9.1 million . The maximum borrowing capacity under the Ares ABL Agreement is based on a formula of eligible accounts receivable and inventory. The Ares ABL Agreement also requires the Company to achieve a minimum quarterly fixed charge coverage ratio for the preceding 12-month period . On September 30, 2015, September 11, 2015 and January 30, 2015, the Company issued 62, 10,000 and 11,525 units of its Series J securities (“Series J Securities”), respectively, to Holdings III and certain other purchasers, at a purchase price of $1,000 per Series J Security for aggregate gross proceeds of $21.6 million. Each Series J Security consists of (i) one share of Series J Convertible Preferred Stock (“Series J Preferred Stock”) and (ii) a warrant to purchase 2,650 shares of Common Stock, at an exercise price of $0.001 per share (the “Series J Warrants”). The Company continues to face challenges in its efforts to achieve positive cash flows from operations and profitability. The Company’s ability to continue to meet its obligations in the ordinary course of business is dependent upon establishing profitable operations, which may be supplemented by any additional funds raised through public or private financing or increased borrowing capacity. The Company’s largest customer, The Home Depot, performed a periodic product line review in June 2015 relating to its entire private label LED lighting product offering. As a result of this line review, the Company entered into a new supplier buying agreement with The Home Depot that is expected to go into full effect in April or May 2016. In connection with the new supplier buying agreement, The Home Depot has elected to purchase certain products previously supplied by the Company directly from overseas suppliers. Such products represented a significant percentage of the Company’s sales to The Home Depot in 2015 and 2014. The Company was, however, selected to supply certain new products to The Home Depot and will continue to supply certain other products that the Company sold to The Home Depot under its prior agreement. In addition, the terms of the new supplier buying agreement with The Home Depot permit the Company to pursue opportunities to sell products to specified big box and other retailers, which was prohibited under its prior agreement. Notwithstanding the new agreement, as was the case under the Company’s prior agreement with The Home Depot, The Home Depot is not required to purchase any minimum amount of products from the Company. As a result of the line review, the Company expects 2016 sales to The Home Depot and, as a result, total revenue, to be significantly reduced. However, because the Company cannot reasonably estimate at this time the extent to which such reduced revenue may be offset by sales of the new products to The Home Depot, as well as by any potential new sales to other retailers, the Company cannot determine at this time the overall impact that the results of The Home Depot line review will have on the Company’s financial condition and operations in the future. As a result of the Company’s historical losses, the Company believes it will likely need to raise additional capital to fund its operations. Sources of additional capital may not be available in an amount or on terms that are acceptable to the Company, if at all. The Company’s complex capital structure, including its obligations to the holders of the outstanding shares of its Preferred Stock (as well as the shares of Series K Preferred Stock that it will be required to issue upon posting the Appeal Bond (as defined below)), may make it more difficult to raise additional capital from new or existing investors or lenders. If the Company is not able to raise such additional capital, the Company may need to restructure or refinance its existing obligations, which restructuring or refinancing would require the consent and cooperation of the Company’s creditors and certain stockholders. In such event, such restructuring or refinancing may not be accomplished on terms that are acceptable to the Company, if at all. If the Company is unable to obtain sufficient capital when needed, the Company’s business, compliance with its credit facilities and future prospects may be adversely affected. RW LSG Holdings LLC (“Riverwood”) and Pegasus each have the right to cause the Company to redeem their shares of Series H Convertible Preferred Stock (“Series H Preferred Stock”) and Series I Convertible Preferred Stock (“Series I Preferred Stock”) and collectively with the Series H Preferred Stock and the Series J Preferred Stock, the “Preferred Stock”), respectively, at any time on or after March 27, 2017. If either Riverwood or Pegasus elects to cause the Company to redeem its shares of Series H Preferred Stock or Series I Preferred Stock, all other holders of the applicable series will similarly have the right to request the redemption of their shares of Preferred Stock. In addition, Portman Limited (“Portman”) and affiliates of Zouk Holdings Limited acting together, have a contractual right to require the Company to redeem their respective shares of Series H Preferred Stock on or after March 27, 2017, subject to certain conditions and limitations. The Company is also required to redeem the outstanding shares of its Series J Preferred Stock (a) subject to certain limited exceptions, immediately prior to the redemption of the Series H Preferred Stock, Series I Preferred Stock or any other security that ranks junior to the Series J Preferred Stock and (b) on November 14, 2019, at the election of the holders of Series J Preferred Stock (a “Special Redemption”). Holders of Preferred Stock would also have the right to require the Company to redeem such shares upon the uncured material breach of the Company’s obligations under its outstanding indebtedness or the uncured material breach of the terms of the certificates of designation governing the Preferred Stock. As of September 30, 2015, in the event the Company was required to redeem all of its outstanding shares of Preferred Stock, the Company’s maximum payment obligation would have been $512.1 million. The Company would be required to repay its outstanding obligations under the Medley Term Loan and the Ares ABL prior to the redemption of any shares of Preferred Stock. As of September 30, 2015, the Company had $35.8 million of aggregate borrowings outstanding under these credit facilities. Any redemption of the Preferred Stock would be limited to funds legally available therefor under Delaware law. The certificates of designation governing the Preferred Stock provide that if there is not a sufficient amount of cash or surplus available to pay for a redemption of Preferred Stock, then the redemption must be paid out of the remaining assets of the Company. In addition, the certificates of designation governing the Preferred Stock provide that the Company is not permitted or required to redeem any shares of Preferred Stock for so long as such redemption would result in an event of default under the Company’s credit facilities. As of September 30, 2015, based solely on a review of the Company’s balance sheet, the Company did not have legally available funds under Delaware law to satisfy a redemption of its Preferred Stock. In addition, based solely on the Company’s projected balance sheet as of March 27, 2017, the Company does not believe that it will have legally available funds on or before March 27, 2017 to satisfy any such redemption. The certificate of designation governing the Series H Preferred Stock also provides that upon the occurrence of a “control event,” the Company must take any and all actions required and permitted to fix the size of its board of directors to a size that would permit Riverwood (as the primary investor of the Series H Preferred Stock) to appoint a majority of the directors to the board until the Company satisfies or otherwise cures the obligations giving rise to the control event. A control event occurs if, among other things, Riverwood exercises its optional redemption right under the certificate of designation governing the Series H Preferred Stock and the Company is unable to redeem Riverwood’s Preferred Stock. If Riverwood were to exercise its optional redemption right and a control event were to occur, Riverwood could take control of the board of directors. The certificate of designation governing the Series J Preferred Stock provides that if the Company does not have sufficient capital available to redeem the Series J Preferred Stock in connection with a Special Redemption of the Series J Preferred Stock, the Company will be required to issue a non-interest bearing note or notes (payable 180 days after issuance) in the principal amount of the liquidation amount of any shares of Series J Preferred Stock not redeemed by the Company in connection with such Special Redemption, subject to certain limitations imposed by Delaware law governing distributions to stockholders. As discussed further in Note 13, one of the Company’s stockholders, Geveran Investments Limited (“Geveran”), filed a lawsuit against the Company and certain other defendants seeking, among other things, rescissionary damages in connection with its $25.0 million investment in the Company. On August 28, 2014, the court presiding over the lawsuit granted Geveran’s motion for partial summary judgment with respect to its cause of action for violation of the Florida securities laws (the “August 28 th at an exercise price that will equal the prevailing market price of our Common Stock immediately prior to the issuance of such warrant. The shares of Series K Preferred Stock will be senior to the Company’s Common Stock and all other series of Preferred Stock. The number of Series K Securities to be issued to Pegasus IV will be determined upon posting the Appeal Bond and will be equal to the quotient obtained by dividing (x) the aggregate amount of the bonds, undertakings, guarantees and/or contractual obligations underlying Pegasus IV’s initial commitment with respect to the Appeal Bond by (y) $1,000. Although the Company cannot predict the ultimate outcome of this lawsuit, it believes the court’s summary judgment award in favor of Geveran is in error and that it has strong defenses against Geveran’s claims. However, in In the event that the Company is not successful on appeal, it could be liable for the full amount of Geveran’s $25.0 million investment, as well as interest, attorneys’ fees and court costs. Accordingly, the summary judgment and the Appeal Bond could have a material adverse effect on the Company’s liquidity and its ability to raise capital in the future.

Note 4 - Detail of Certain Bala

Note 4 - Detail of Certain Balance Sheet Accounts	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	Note 4. Detail of Certain Balance Sheet Accounts Inventories Inventories consisted primarily of finished goods as of September 30, 2015 and December 31, 2014. As of September 30, 2015 and December 31, 2014, inventories were stated net of inventory write downs of $4.7 million and $7.9 million, respectively. The Company considered a number of factors in estimating the required inventory write downs, including (i) the focus of the business on the next generation of the Company’s products, which utilize lower cost technologies, (ii) the strategic focus on core products to meet the demands of key customers and (iii) the expected demand for the Company’s current generation of products, which is approaching the end of its lifecycle upon the introduction of the next generation of products. Property and Equipment, Net Depreciation related to property and equipment was $454 ,000 and $599,000 for the three months ended September 30, 2015 and 2014, respectively. Depreciation related to property and equipment was $1.4 million and $2.6 million for the nine months ended September 30, 2015 and 2014, respectively. Intangible Assets Intangible assets that have finite lives are amortized over their useful lives. The Company’s intangible assets as of September 30, 2015 and December 31, 2014 are detailed below: Cost, Less Impairment Charges Accumulated Amortization Net Book Value Estimated Remaining Useful Life (years) September 30, 2015: Technology and intellectual property $ 3,091,026 $ (285,651 ) $ 2,805,375 0.9 to 20.0 December 31, 2014: Technology and intellectual property $ 2,796,580 $ (224,101 ) $ 2,572,479 2.7 to 20.0 Total intangible asset amortization expense was $21,000 and $17,000 for the three months ended September 30, 2015 and 2014, respectively. Total intangible asset amortization expense was $62 ,000 and $46,000 for the nine months ended September 30, 2015 and 2014, respectively.

Note 5 - Debt Issuance Costs

Note 5 - Debt Issuance Costs	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Debt Issuance Costs [Text Block]	Note 5. Debt Issuance Costs The Company capitalizes its costs related to the issuance of long-term debt and amortizes these costs using the effective interest rate method over the life of the loan. Amortization of debt issuance costs and the accelerated write-off of debt issuance costs in connection with refinancing activities are recorded as a component of interest expense. As of September 30, 2015, the current portion of the debt issuance costs was $1.6 million and was included in other current assets. In connection with the Ares ABL and the Medley Term Loan, $6.0 million of debt issuance costs were capitalized, including $2.8 million related to the fair value of the guaranty of the Company’s obligations under the Medley Loan Agreement in favor of Medley (the “Pegasus Guaranty”) provided by Pegasus Capital Partners IV, L.P. and Pegasus Capital Partners V, L.P. (collectively, the “Pegasus Guarantors”). The Company amortized $398,000 and $312,000 of debt issuance costs for the three months ended September 30, 2015 and 2014, respectively. The Company amortized $1.1 million and $1.3 million of debt issuance costs for the nine months ended September 30, 2015 and 2014, respectively .

Note 6 - Lines of Credit and No

Note 6 - Lines of Credit and Note Payable	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 6. Lines of Credit and Note Payable Facility September 30, 2015 December 31, 2014 FCC ABL, revolving line of credit $ 6,960,340 $ 6,368,793 Medley Term Loan 28,871,320 27,813,061 $ 35,831,660 $ 34,181,854 Ares ABL On April 25, 2014, the Company, entered into the Ares ABL, which provides the Company with a maximum borrowing capacity of $22.5 million, which capacity is based on a formula of eligible accounts receivable and inventory. As of September 30, 2015, the Company had additional borrowing capacity of $9.1 million. As of September 30 2015, eligible collateral included $6.6 million of accounts receivable and $10.0 million of inventory. Borrowings under the Ares ABL bear interest at a floating rate equal to one -month LIBOR plus 5.5% per annum . As of September 30, 2015, the interest rate on the Ares ABL was 5.7%. On September 11, 2015, the Company entered into an amendment to the Ares ABL, which among other things (i) increased the interest margin payable under the Ares ABL by 150 basis points, such that the interest accrues on the outstanding borrowings at a rate equal to LIBOR plus 5.5%, (ii) provided for a mandatory repayment in full of the obligations under the Ares ABL if the Company redeems the Series K Preferred Stock, (iii) allows the Company to enter into the Appeal Bond and certain related agreements without further consent or approval from Ares, (iv) provides that the Company must notify Ares of entry of the August 28 th . Medley Term Loan On February 19, 2014, the Company entered into the Medley Term Loan, which provided the Company with a $30.5 million term loan facility. The Medley Term Loan bears interest at a floating rate equal to three-month LIBOR plus 12% per annum, and as of September 30, 2015, the interest rate on the Medley Term Loan was 12.33%. Additionally, $3.0 million of the Medley Term Loan was funded directly into a deposit account to which Medley has exclusive access, to further secure the loan. The outstanding principal balance and all accrued and unpaid interest on the Medley Term Loan are due and payable on February 19, 2019. The Company recognized $195,000 of interest expense for the accretion of the discounts to the balance of the Medley Term Loan related to commitment fees and the Medley Warrants for both the three months ended September 30, 2015 and 2014, and $160,000 and $157,000 of accrued interest for the three months ended September 30, 2015 and 2014, respectively. The Company recognized $584,000 of interest expense for the accretion of the discounts to the balance of the Medley Term Loan related to commitment fees and the Medley Warrants and $474,000 of accrued interest for the nine months ended September 30, 2015, and $474,000 of interest expense for the accretion of the discounts to the balance of the Medley Term Loan related to the commitment fees and the Medley Warrants and $382,000 of accrued interest for the period from February 19, 2014 (date of issuance) to September 30, 2014. On September 11, 2015, the Company entered into an amendment to the Medley Term Loan, which among other things, (i) amends the minimum EBITDA covenant levels with respect to each of the twelve-month period ended September 30, 2015, the twelve-month period ending December 31, 2015, the twelve-month period ending March 31, 2016 and the twelve-month period ending June 30, 2016 (collectively, the “ Specified Covenant Periods ”) to provide that a portion of the cash proceeds from the sale of Series J Securities on September 11, 2015 will be included in the calculation of EBITDA for such periods, (ii) amends the definition of “Fixed Charge Coverage Ratio” in the Medley Term Loan Agreement to provide that $10.0 million of the cash proceeds from the September 11, 2015 offering will be included in EBITDA for purposes of calculating the “Fixed Charge Coverage Ratio” for each of the Specified Covenant Periods, (iii) allows the Company to enter into the Appeal Bond and certain related agreements without further consent or approval from Medley and (iv) adds certain events of default relating to the Geveran litigation .

Note 7 - Fair Value Measurement

Note 7 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 7. Fair Value Measurements The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2015, according to the valuation techniques the Company used to determine their fair values: Fair Value Measurement as of September 30, 2015 Quoted Price in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Level 1 Level 2 Level 3 Assets (Recurring): Pegasus Commitment $ - $ - $ 286,400 Liabilities (Recurring): Riverwood Warrants $ - $ - $ 2,817,004 September 2012 Warrants - - 286,400 Pegasus Warrant - - 1,557,000 THD Warrant - - 120,082 Medley Warrants - - 896,354 Pegasus Guaranty Warrants - - 1,026,214 $ - $ - $ 6,703,054 The following table is a reconciliation of the beginning and ending balances for assets and liabilities that were accounted for at fair value on a recurring basis using Level 3 inputs , as defined above , for the nine months ended September 30, 2015: Balance Realized and unrealized Purchases, sales, Transfers in Balance Pegasus Commitment $ 720,000 $ (433,600 ) $ - $ - $ 286,400 Riverwood Warrants (2,352,027 ) (464,977 ) - - (2,817,004 ) September 2012 Warrants (720,000 ) 433,600 - - (286,400 ) Pegasus Warrant (1,300,000 ) (257,000 ) - - (1,557,000 ) THD Warrant (43,928 ) (76,154 ) - - (120,082 ) Medley Warrants (577,065 ) (319,289 ) - - (896,354 ) Pegasus Guaranty Warrants (643,924 ) (382,290 ) - - (1,026,214 ) Total $ (4,916,944 ) $ (1,499,710 ) $ - $ - $ (6,416,654 ) The following table is a reconciliation of the beginning and ending balances for assets and liabilities that were accounted for at fair value on a recurring basis using Level 3 inputs , as defined above , for the nine months ended September 30, 2014: Balance Realized and unrealized Purchases, sales, Transfers in Balance Pegasus Commitment $ 1,407,335 $ (367,335 ) $ - $ - $ 1,040,000 Riverwood Warrants (5,002,664 ) 1,746,011 - - (3,256,653 ) September 2012 Warrants (1,407,335 ) 367,335 - - (1,040,000 ) Pegasus Warrant (2,765,047 ) 965,047 - - (1,800,000 ) THD Warrant - (39,867 ) - (74,576 ) (114,443 ) Series J Warrants - (25,140,561 ) (12,505,739 ) 37,646,300 - Medley Warrants - 1,847,049 (3,170,361 ) - (1,323,312 ) Pegasus Guaranty Warrants - 1,901,193 (3,336,574 ) - (1,435,381 ) Total $ (7,767,711 ) $ (18,721,128 ) $ (19,012,674 ) $ 37,571,724 $ (7,929,789 )

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 8. Stockholders’ Equity For the three months ended September 30, 2015 and 2014, the Company recorded expense of $128 ,000 and $221,000, respectively, related to restricted stock awards to the Company’s directors. For the nine months ended September 30, 2015 and 2014, the Company recorded expense of $258,000 and $412,000, respectively, related to restricted stock awards to the Company’s directors. On June 12, 2014, the Board approved the formation of a Scientific Advisory Board (the “SAB”) and issued restricted stock awards to each of the five members of the SAB as part of their compensation package. For the three and nine months ended September 30, 2015, the Company recorded expense of $0 and $37,000, respectively, related to restricted stock awards to the Company’s SAB. For the three and nine months ended September 30, 2014, the Company recorded expense of $26,000 and $31,000, respectively, related to restricted stock awards to the Company’s SAB. Warrants for the Purchase of Common Stock As of September 30, 2015, the following warrants for the purchase of Common Stock were outstanding: Warrant Holder Reason for Issuance Number of Common Shares Exercise Price Expiration Date Investors in rights offering Series D Warrants 1,192,048 $ 2.65 to $2.66 March 3, 2022 through April 19, 2022 The Home Depot Purchasing agreement 8,456,432 $ 0.95 December 31, 2015 through 2018 RW LSG Management Holdings LLC Riverwood Warrants 12,664,760 Variable May 25, 2022 Certain other investors Riverwood Warrants 5,427,751 Variable May 25, 2022 Cleantech Europe II (A) LP September 2012 Warrants 3,406,041 $ 0.72 September 25, 2022 Cleantech Europe II (B) LP September 2012 Warrants 593,959 $ 0.72 September 25, 2022 Portman Limited September 2012 Warrants 4,000,000 $ 0.72 September 25, 2022 Aquillian Investments LLC Private Placement Series H 830,508 $ 1.18 September 25, 2017 Pegasus Pegasus Warrant 10,000,000 Variable May 25, 2022 Investors in Series J Follow-On Offering Series J Warrants 212,164,300 $ 0.001 January 3, 2019 through January 30, 2020 Medley Medley Warrants 10,000,000 $ 0.95 February 19, 2024 Pegasus Pegasus Guaranty Warrants 10,000,000 $ 0.50 February 19, 2024 278,735,799

Note 9 - Earnings (Loss) Per Sh

Note 9 - Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 9: Earnings (Loss) Per Share In 2012, the Company determined that two classes of Common Stock had been established for financial reporting purposes only, with Common Stock attributable to controlling stockholders representing shares beneficially owned and controlled by Pegasus and the Common Stock attributable to noncontrolling stockholders representing the minority interest stockholders. For the three and nine months ended September 30, 2015 and 2014, the Company computed net loss per share of noncontrolling stockholders and controlling stockholders of Common Stock using the two-class method. Net loss from operations is initially allocated based on the underlying common shares held by controlling and noncontrolling stockholders. The allocation of the net losses attributable to the Common Stock attributable to controlling stockholders is then reduced by the amount of the deemed dividend related to the warrants issued to the Pegasus Guarantors, while the allocation of net losses attributable to the Common Stock attributable to noncontrolling stockholders is increased by the amount of the deemed dividend related to the warrants issued to the Pegasus Guarantors. The following table sets forth the computation of basic and diluted net loss per share of Common Stock: For the Three Months Ended September 30, 2015 2014 Controlling Stockholders Noncontrolling Stockholders Controlling Stockholders Noncontrolling Stockholders Basic and diluted net income (loss) per share: Net loss attributable to common stock $ 203,149 $ 66,195 $ (1,686,077 ) $ (416,499 ) Deemed dividends related to the Series J Preferred Stock attributable to all shareholders (11,742,251 ) (3,826,160 ) (9,571,504 ) (2,364,374 ) Undistributed net loss $ (11,539,102 ) $ (3,759,965 ) $ (11,257,581 ) $ (2,780,873 ) Basic and diluted weighted average number of common shares outstanding 303,817,578 98,997,606 255,194,735 63,038,781 Basic and diluted net loss per common share $ (0.04 ) $ (0.04 ) $ (0.04 ) $ (0.04 ) For the Nine Months Ended September 30, 2015 2014 Controlling Stockholders Noncontrolling Stockholders Controlling Stockholders Noncontrolling Stockholders Basic and diluted net income per share: Net loss attributable to common stock $ (11,841,266 ) $ (3,934,793 ) $ (43,394,934 ) $ (10,430,121 ) Deemed dividends due to the issuance of Pegasus Guaranty Warrants as compensation for guaranty provided by controlling shareholders - - 570,574 (570,574 ) Deemed dividends related to the Series J Preferred Stock attributable to all shareholders (23,178,283 ) (7,702,028 ) (34,077,591 ) (8,190,666 ) Undistributed net loss $ (35,019,549 ) $ (11,636,821 ) $ (76,901,951 ) $ (19,191,361 ) Basic and diluted weighted average number of common shares outstanding 296,699,120 98,591,636 220,629,709 53,029,108 Basic and diluted net loss per common share $ (0.12 ) $ (0.12 ) $ (0.35 ) $ (0.36 ) Basic earnings per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding for the applicable period. The Series J Warrants have an exercise price of $0.001 per share of Common Stock, and are included in the weighted average number of shares of Common Stock outstanding as there are no conditions that must be satisfied before such warrant may be exercised into the shares of Common Stock underlying such warrants. Diluted earnings per share is computed in the same manner as basic earnings per share except the number of shares is increased to assume exercise of potentially dilutive stock options, unvested restricted stock and contingently issuable shares using the treasury stock method and convertible preferred shares using the if-converted method, unless the effect of such increases would be anti-dilutive. The Company had 213.3 million and 177.1 million common stock equivalents for the three months ended September 30 , 2015 and 2014, respectively, and 209.8 million and 190.4 million common stock equivalents for the nine months ended September 30 , 2015 and 2014, respectively, which were not included in the diluted net loss per common share as the common stock equivalents were anti-dilutive, as a result of the Company being in a net loss position.

Note 10 - Related Party Transac

Note 10 - Related Party Transactions	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 10: Related Party Transactions Pegasus Capital is an affiliate of Pegasus IV and LSGC Holdings, which are the Company’s largest stockholders and beneficially owned approximately 90.0% of the Common Stock as of September 30, 2015. On September 11, 2015 and January 30, 2015, the Company issued an additional 10,000 and 11,525 units of Series J Securities, at a purchase price of $1,000 per Series J Security for aggregate gross proceeds of $21.5 million. The Series J Securities were issued pursuant to subscription agreements between the Company and Holdings III, an affiliate of Pegasus Capital.

Note 11 - Restructuring Expense

Note 11 - Restructuring Expense	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	Note 11. Restructuring Expense The following table summarizes the Company’s restructuring expense and related charges for the periods indicated: For the Nine Months Ended September 30, 2015 2014 Broad based reduction of facilities and personnel (1) $ 297,770 $ 2,558,072 Organization Optimization Initiative (2) - 114,278 Total $ 297,770 $ 2,672,350 (1) These charges relate to a significant cost reduction plan initiated during the fourth quarter of 2013 that includes outsourcing of a majority of the Company’s manufacturing to its contract manufacturers in Asia, related workforce reductions in Satellite Beach, Florida and cost reductions in its foreign subsidiaries. The Company estimates it will incur $200,000 in additional expenses throughout this cost reduction plan, primarily related to additional headcount reductions. These additional costs are expected to be incurred during 2015. (2) In September 2011, the Company initiated a restructuring plan designed to further increase efficiencies across the organization and lower the overall cost structure. In 2012, the Company extended the restructuring plan to further increase efficiencies across the organization and lower its overall cost structure. The plan included a significant reduction in full time headcount and the closing of the Company’s offices in the United Kingdom and Australia. For the nine months ended September 30, 2014, these expenses related to the final liquidation of the Australian entity . As of September 30, 2015, the accrued liability associated with the restructuring and other related charges consisted of the following: Workforce Excess Other Total Accrued liability as of December 31, 2014 $ 959,240 $ 353,269 $ 138,840 $ 1,451,349 Charges 297,770 - - 297,770 Payments (1,162,030 ) (82,247 ) (1,013 ) (1,245,290 ) Accrued liability as of September 30, 2015 $ 94,980 $ 271,022 $ 137,827 $ 503,829 The remaining accrual of $504 ,000 as of September 30, 2015 is expected to be paid during the year ending December 31, 2016. The restructuring and other related charges are included in the line item restructuring expense in the condensed consolidated statement of operations and comprehensive loss.

Note 12 - Concentrations of Cre

Note 12 - Concentrations of Credit Risk	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 12. Concentrations of Credit Risk For the three months ended September 30, 2015 and 2014, revenue derived from sales to The Home Depot represented 89% and 82%, respectively, of the Company’s total revenue. For the nine months ended September 30, 2015 and 2014, revenue derived from sales to The Home Depot represented 88% and 78%, respectively, of total revenue. As of September 30, 2015 and December 31, 2014, The Home Depot accounts receivable balance represented 78% and 77%, respectively, of the Company’s total accounts receivable, net of allowances.

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 13. Commitments and Contingencies The Company is subject to the possibility of loss contingencies arising in its business. Such contingencies are accounted for in accordance with ASC Topic 450, “Contingencies.” In determining loss contingencies, the Company considers the possibility of a loss and the ability to reasonably estimate the amount of such loss or liability. An estimated loss is recorded when it is considered probable that a liability has been incurred and when the amount of loss can be reasonably estimated. 16 Legal Proceedings In the ordinary course of business, the Company is routinely a party to various pending and threatened legal claims and proceedings. While the ultimate outcome of these matters cannot be predicted with certainty, based on information currently available and advice of counsel, and taking into account available insurance coverage, except as noted below, the Company does not believe that the outcome of any of these claims will have a material adverse effect on its business, financial condition or results of operations. However, the results of legal proceedings cannot be predicted with certainty, and in the event of unexpected future developments the ultimate resolution of one or more of these matters could be unfavorable. Should the Company fail to prevail in any of these legal matters or should several of these legal matters be resolved against the Company in the same reporting period, the consolidated financial position or operating results could be materially adversely affected. Regardless of the outcome, any litigation may require the Company to incur significant expenses and may result in significant diversion of management’s attention. Further, during its ordinary course of business, the Company enters into obligations to defend, indemnify and/or hold harmless various customers, officers, directors, employees, and other third parties. These contractual obligations could give rise to additional litigation costs and involvement in court proceedings. Geveran Investments Limited v. Lighting Science Group Corporation, et al . (the “Geveran Case”) On June 22, 2012, Geveran Investments Limited (“Geveran”), one of the Company’s stockholders, filed a lawsuit against the Company and several other defendants in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida. On October 30, 2012, the court entered an order transferring the lawsuit to the Ninth Judicial Circuit in and for Orange County, Florida. The Geveran Case names the Company as a defendant, as well as Pegasus Capital and nine other entities affiliated with Pegasus Capital; Richard Weinberg, our former Director and former interim Chief Executive Officer and a former partner of Pegasus Capital; Gregory Kaiser, a former Chief Financial Officer; J.P. Morgan Securities, LLC (“J.P. Morgan”); and two employees of J.P. Morgan. Geveran seeks rescissionary damages in connection with its $25.0 million investment in the Company, as well as recovery of interest, attorneys’ fees and court costs, jointly and severally against the Company, Pegasus Capital, Mr. Weinberg, Mr. Kaiser, J.P. Morgan and the two J.P. Morgan employees, for alleged violations of Florida securities laws. Geveran alternatively seeks unspecified money damages, as well as recovery of court costs, for alleged common law negligent misrepresentation against these same defendants. In August 2014, the court granted Geveran’s motion to amend their first amended complaint to assert a claim for punitive damages against the defendants. On August 28, 2014, the court issued the August 28 th While the outcome of any appeal is inherently difficult to predict, the Company believes that the trial court’s grant of summary judgment to plaintiff was in error. In the event that the summary judgment is overturned on appeal, and the case were to be remanded back to the trial court for further proceedings , the Company believes it has strong defenses against Geveran’s claims. The Company denies liability in connection with this matter and intends to continue to vigorously defend itself against the claims asserted by Geveran. However, in the event that the Company is not successful on appeal, it could be liable for the full amount of Geveran’s $25.0 million investment, as well as interest, attorneys’ fees and court costs. Even if the Company is successful on appeal and the case were to be remanded back to the trial court for further proceedings, the amount of possible loss, if any, cannot be reasonably estimated at this time. The Company believes that, subject to the terms and conditions of the relevant policies (including retention and policy limits), directors’ and officers’ insurance coverage will be available to cover the substantial majority of its legal fees and costs in this matter. However, given the unspecified nature of Geveran’s maximum damage claims, insurance coverage may not be available for, or such coverage may not be sufficient to fully pay, a judgment or settlement in favor of Geveran. Based upon the terms of an indemnification agreement described below, the Company has also paid, and is likely to pay in the in the future, reasonable legal expenses incurred by J.P. Morgan and its affiliates in this lawsuit in connection with the engagement of J.P. Morgan as placement agent for the private placement with Geveran. Such payments are not covered by the Company’s insurance policies. The engagement letter executed with J.P. Morgan provides that the Company will indemnify J.P. Morgan and its affiliates from liabilities relating to J.P. Morgan’s activities as placement agent, unless such activities are finally judicially determined to have resulted from J.P. Morgan’s bad faith, gross negligence or willful misconduct. Accordingly, the outcome of the Geveran Case, if unfavorable, would likely have a material adverse effect on the Company’s financial position. 17 GE Lighting Solutions v. Lighting Science Group Corporation , et al. The Company is also a defendant in an action brought by GE Lighting Solutions LLC (“GE Lighting”) in Federal District Court for the Northern District of Ohio in or about January 2013. GE Lighting asserts a claim of infringement by the Company, as well as five other LED manufacturers, of U.S . Patent No. 6,787,999, entitled LED-Based Modular High Power LED Power Pack for Spot Module Illumination . Other In addition, the Company may be a party to a variety of legal actions, such as employment and employment discrimination-related suits, employee benefit claims, breach of contract actions, tort claims, shareholder suits, including securities fraud, intellectual property related litigation, and a variety of legal actions relating to its business operations. In some cases, substantial punitive damages may be sought. The Company currently has insurance coverage for certain of these potential liabilities. Other potential liabilities may not be covered by insurance, insurers may dispute coverage or the amount of insurance may not be sufficient to cover the damages awarded. In addition, certain types of damages, such as punitive damages, may not be covered by insurance and insurance coverage for all or certain forms of liability may become unavailable or prohibitively expensive in the future.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Financial Statement Presentation The accompanying unaudited condensed consolidated financial statements are presented pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) in accordance with the disclosure requirements for the quarterly report on Form 10-Q and therefore do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) necessary to fairly state the results for the interim periods presented. The condensed consolidated balance sheet as of December 31, 2014 is derived from the Company’s audited financial statements. Operating results for the three and nine months ended September 30, 2015 are not necessarily indicative of the results of the Company that may be expected for the year ending December 31, 2015. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2014 and notes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on March 31, 2015. The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in the accompanying condensed consolidated financial statements.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. The Company’s actual results could differ from these estimates.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash As of September 30, 2015 and December 31, 2014, as required by the Company’s five-year term loan (as amended from time to time, the “Medley Term Loan”) with Medley Capital Corporation (“Medley”), the Company maintained a minimum restricted cash balance of $3.0 million to collateralize the Medley Term Loan. Changes in the restricted cash balance are reflected as a financing activity in the consolidated statement of cash flows.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Accounts Receivable The Company records accounts receivable at the invoiced amount when its products are shipped to customers or when specific milestone billing requirements are completed. The Company’s accounts receivable balance is recorded net of allowances for amounts not expected to be collected from customers. This allowance for doubtful accounts is the Company’s best estimate of probable credit losses in the Company’s existing accounts receivable. Estimates used in determining the allowance for doubtful accounts are based on historical collection experience, age of receivables and known collectability issues. The Company writes off accounts receivable when it becomes apparent, based on age or customer circumstances, that such amounts will not be collected. The Company reviews its allowance for doubtful accounts on a quarterly basis. Recovery of bad debt amounts previously written off is recorded as a reduction of bad debt expense in the period the payment is collected. Generally, the Company does not require collateral for its accounts receivable and does not regularly charge interest on past due amounts. As of September 30, 2015 and December 31, 2014, the Company’s accounts receivable were reflected net of an allowance for doubtful accounts of $483 ,000 and $408,000, respectively. As of September 30, 2015 and December 31, 2014, $6.6 million and $5.4 million, respectively, of eligible accounts receivable were pledged as collateral for the three-year asset based revolving credit facility (as amended from time to time, the “FCC ABL”) entered into on April 25, 2014 with FCC, LLC d/b/a First Capital (“First Capital”). First Capital sold the FCC ABL to ACF Finco I LP (“Ares”) in May 2015, and the FCC ABL is hereinafter referred to as the “Ares ABL.”
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company records revenue when its products are shipped and title passes to customers. When sales of products are subject to certain customer acceptance terms, revenue from such sales is recognized once those terms have been met. The Company also provides its customers with limited rights of return for non-conforming shipments or product warranty claims. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”). ASU 2014-09 seeks to clarify the principles for recognizing revenue and to develop a common revenue standard for GAAP and International Financial Reporting Standards. ASU 2014-09 initially was effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. However, at its July 9, 2015 meeting, the FASB agreed to defer by one year the mandatory effective date of this standard, but will also provide the option to adopt it as of the original effective date. The Company is currently evaluating the impact of adopting ASU 2014-09, but the standard is not expected to have a significant effect on its consolidated financial statements.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranties The Company generally provides a five-year limited warranty covering defective materials and workmanship of its products. Such warranty may require the Company to repair, replace or reimburse the purchaser for the purchase price of the product. The estimated costs related to warranties are accrued at the time products are sold based on various factors, including the Company’s stated warranty policies and practices, the historical frequency of claims and the cost to repair or replace its products under warranty. The warranty provision is included in accrued expenses on the condensed consolidated balance sheet. Changes in the warranty provision for the nine months ended September 30, 2015 were as follows: Warranty provision as of December 31, 2014 $ 4,789,470 Additions to provision 1,422,333 Less warranty costs (2,518,190 ) Warranty provision as of September 30, 2015 $ 3,693,613
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Measurements The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: • Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. • Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. • Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. Fair Value of Financial Instruments Cash and cash equivalents, accounts receivable, accounts payable, amounts due under lines of credit and other short term borrowings, accrued expenses and the note payable are carried at amounts that approximate their fair value due to the short-term maturity of these instruments and/or variable, market driven interest rates. The liabilities under derivative contracts, which represent warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), were initially recorded at fair value and subsequently reflected at their fair value at the end of each reporting period. The fair value of the warrant issued to The Home Depot, Inc. (the “THD Warrant”) in January 2011 is determined using the Monte Carlo valuation method and will be adjusted at each reporting date until the underlying shares have been earned for each year. Such adjustments will be recorded as a reduction in the related revenue (sales incentive) from The Home Depot, Inc. (“The Home Depot”). Once a portion of the THD Warrant vests it is recorded at its fair value at the end of each subsequent reporting period.
Reclassification, Policy [Policy Text Block]	Reclassification Certain prior period amounts in the accompanying consolidated financial statements have been reclassified to conform to the current year presentation. These reclassifications had no effect on previously reported net loss or stockholders’ deficit.

Note 2 - Summary of Significa22

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2015
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]	Warranty provision as of December 31, 2014 $ 4,789,470 Additions to provision 1,422,333 Less warranty costs (2,518,190 ) Warranty provision as of September 30, 2015 $ 3,693,613

Note 4 - Detail of Certain Ba23

Note 4 - Detail of Certain Balance Sheet Accounts (Tables)	9 Months Ended
	Sep. 30, 2015
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Cost, Less Impairment Charges Accumulated Amortization Net Book Value Estimated Remaining Useful Life (years) September 30, 2015: Technology and intellectual property $ 3,091,026 $ (285,651 ) $ 2,805,375 0.9 to 20.0 December 31, 2014: Technology and intellectual property $ 2,796,580 $ (224,101 ) $ 2,572,479 2.7 to 20.0

Note 6 - Lines of Credit and 24

Note 6 - Lines of Credit and Note Payable (Tables)	9 Months Ended
	Sep. 30, 2015
Notes Tables
Schedule of Debt [Table Text Block]	Facility September 30, 2015 December 31, 2014 FCC ABL, revolving line of credit $ 6,960,340 $ 6,368,793 Medley Term Loan 28,871,320 27,813,061 $ 35,831,660 $ 34,181,854

Note 7 - Fair Value Measureme25

Note 7 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2015
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value Measurement as of September 30, 2015 Quoted Price in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Level 1 Level 2 Level 3 Assets (Recurring): Pegasus Commitment $ - $ - $ 286,400 Liabilities (Recurring): Riverwood Warrants $ - $ - $ 2,817,004 September 2012 Warrants - - 286,400 Pegasus Warrant - - 1,557,000 THD Warrant - - 120,082 Medley Warrants - - 896,354 Pegasus Guaranty Warrants - - 1,026,214 $ - $ - $ 6,703,054
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Balance Realized and unrealized Purchases, sales, Transfers in Balance Pegasus Commitment $ 720,000 $ (433,600 ) $ - $ - $ 286,400 Riverwood Warrants (2,352,027 ) (464,977 ) - - (2,817,004 ) September 2012 Warrants (720,000 ) 433,600 - - (286,400 ) Pegasus Warrant (1,300,000 ) (257,000 ) - - (1,557,000 ) THD Warrant (43,928 ) (76,154 ) - - (120,082 ) Medley Warrants (577,065 ) (319,289 ) - - (896,354 ) Pegasus Guaranty Warrants (643,924 ) (382,290 ) - - (1,026,214 ) Total $ (4,916,944 ) $ (1,499,710 ) $ - $ - $ (6,416,654 ) Balance Realized and unrealized Purchases, sales, Transfers in Balance Pegasus Commitment $ 1,407,335 $ (367,335 ) $ - $ - $ 1,040,000 Riverwood Warrants (5,002,664 ) 1,746,011 - - (3,256,653 ) September 2012 Warrants (1,407,335 ) 367,335 - - (1,040,000 ) Pegasus Warrant (2,765,047 ) 965,047 - - (1,800,000 ) THD Warrant - (39,867 ) - (74,576 ) (114,443 ) Series J Warrants - (25,140,561 ) (12,505,739 ) 37,646,300 - Medley Warrants - 1,847,049 (3,170,361 ) - (1,323,312 ) Pegasus Guaranty Warrants - 1,901,193 (3,336,574 ) - (1,435,381 ) Total $ (7,767,711 ) $ (18,721,128 ) $ (19,012,674 ) $ 37,571,724 $ (7,929,789 )

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2015
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant Holder Reason for Issuance Number of Common Shares Exercise Price Expiration Date Investors in rights offering Series D Warrants 1,192,048 $ 2.65 to $2.66 March 3, 2022 through April 19, 2022 The Home Depot Purchasing agreement 8,456,432 $ 0.95 December 31, 2015 through 2018 RW LSG Management Holdings LLC Riverwood Warrants 12,664,760 Variable May 25, 2022 Certain other investors Riverwood Warrants 5,427,751 Variable May 25, 2022 Cleantech Europe II (A) LP September 2012 Warrants 3,406,041 $ 0.72 September 25, 2022 Cleantech Europe II (B) LP September 2012 Warrants 593,959 $ 0.72 September 25, 2022 Portman Limited September 2012 Warrants 4,000,000 $ 0.72 September 25, 2022 Aquillian Investments LLC Private Placement Series H 830,508 $ 1.18 September 25, 2017 Pegasus Pegasus Warrant 10,000,000 Variable May 25, 2022 Investors in Series J Follow-On Offering Series J Warrants 212,164,300 $ 0.001 January 3, 2019 through January 30, 2020 Medley Medley Warrants 10,000,000 $ 0.95 February 19, 2024 Pegasus Pegasus Guaranty Warrants 10,000,000 $ 0.50 February 19, 2024 278,735,799

Note 9 - Earnings (Loss) Per 27

Note 9 - Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2015
Third Quarter [Member]
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	For the Three Months Ended September 30, 2015 2014 Controlling Stockholders Noncontrolling Stockholders Controlling Stockholders Noncontrolling Stockholders Basic and diluted net income (loss) per share: Net loss attributable to common stock $ 203,149 $ 66,195 $ (1,686,077 ) $ (416,499 ) Deemed dividends related to the Series J Preferred Stock attributable to all shareholders (11,742,251 ) (3,826,160 ) (9,571,504 ) (2,364,374 ) Undistributed net loss $ (11,539,102 ) $ (3,759,965 ) $ (11,257,581 ) $ (2,780,873 ) Basic and diluted weighted average number of common shares outstanding 303,817,578 98,997,606 255,194,735 63,038,781 Basic and diluted net loss per common share $ (0.04 ) $ (0.04 ) $ (0.04 ) $ (0.04 )
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	For the Nine Months Ended September 30, 2015 2014 Controlling Stockholders Noncontrolling Stockholders Controlling Stockholders Noncontrolling Stockholders Basic and diluted net income per share: Net loss attributable to common stock $ (11,841,266 ) $ (3,934,793 ) $ (43,394,934 ) $ (10,430,121 ) Deemed dividends due to the issuance of Pegasus Guaranty Warrants as compensation for guaranty provided by controlling shareholders - - 570,574 (570,574 ) Deemed dividends related to the Series J Preferred Stock attributable to all shareholders (23,178,283 ) (7,702,028 ) (34,077,591 ) (8,190,666 ) Undistributed net loss $ (35,019,549 ) $ (11,636,821 ) $ (76,901,951 ) $ (19,191,361 ) Basic and diluted weighted average number of common shares outstanding 296,699,120 98,591,636 220,629,709 53,029,108 Basic and diluted net loss per common share $ (0.12 ) $ (0.12 ) $ (0.35 ) $ (0.36 )

Note 11 - Restructuring Expen28

Note 11 - Restructuring Expense (Tables)	9 Months Ended
	Sep. 30, 2015
Notes Tables
Restructuring and Related Costs [Table Text Block]	For the Nine Months Ended September 30, 2015 2014 Broad based reduction of facilities and personnel (1) $ 297,770 $ 2,558,072 Organization Optimization Initiative (2) - 114,278 Total $ 297,770 $ 2,672,350
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	Workforce Excess Other Total Accrued liability as of December 31, 2014 $ 959,240 $ 353,269 $ 138,840 $ 1,451,349 Charges 297,770 - - 297,770 Payments (1,162,030 ) (82,247 ) (1,013 ) (1,245,290 ) Accrued liability as of September 30, 2015 $ 94,980 $ 271,022 $ 137,827 $ 503,829

Note 2 - Summary of Significa29

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Mar. 01, 2014	Sep. 30, 2015	Dec. 31, 2014
Medley Term Loan [Member] | Minimum [Member]
Restricted Cash and Cash Equivalents, Current		$ 3,000,000	$ 3,000,000
First Capital [Member]
Debt Instrument, Collateral Amount		$ 6,600,000	5,400,000
Medley Term Loan [Member]
Debt Instrument, Term	5 years	5 years
Restricted Cash and Cash Equivalents, Current		$ 3,000,000
Allowance for Doubtful Accounts Receivable		$ 483,000	$ 408,000
Products Warranty Period		5 years
Common Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001

Note 2 - Summary of Significa30

Note 2 - Summary of Significant Accounting Policies - Summary of Warranty Provision (Details)	9 Months Ended
	Sep. 30, 2015USD ($)
Warranty provision	$ 4,789,470
Additions to provision	1,422,333
Less warranty costs	(2,518,190)
Warranty provision	$ 3,693,613

Note 3 - Liquidity and Capita31

Note 3 - Liquidity and Capital Resources (Details Textual) - USD ($)	Sep. 30, 2015	Sep. 11, 2015	Jan. 30, 2015	Mar. 01, 2014	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Feb. 19, 2014	Dec. 31, 2013
Series J Preferred Stock [Member] | Holdings III [Member ] | Series J Redeemable Convertible Preferred Stock [Member]
Share Price	$ 1,000	$ 1,000	$ 1,000		$ 1,000
Convertible Preferred Stock, Shares Issued upon Conversion	1	1	1		1
Stock Issued During Period, Shares, New Issues	62	10,000	11,525
Proceeds from Issuance of Redeemable Preferred Stock					$ 21,600,000
Series K Preferred Stock [Member]
Share Price	$ 1,000				$ 1,000
Convertible Preferred Stock, Shares Issued upon Conversion	1				1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	735				735
Series J Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	2,650	2,650	2,650		2,650
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.001	$ 0.001	$ 0.001		$ 0.001
Medley Term Loan [Member]
Debt Instrument, Term				5 years	5 years
Line of Credit Facility, Maximum Borrowing Capacity								$ 30,500,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								5,000,000
First Capital [Member]
Debt Instrument, Term					3 years
Line of Credit Facility, Maximum Borrowing Capacity	$ 22,500,000				$ 22,500,000
Line of Credit, Current	7,000,000				7,000,000
Line of Credit Facility, Remaining Borrowing Capacity	$ 9,100,000				9,100,000
Geveran Case [Member]
Loss Contingency, Damages Sought, Value					$ 25,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights
Retained Earnings (Accumulated Deficit)	$ (816,104,632)				$ (816,104,632)	$ (800,328,573)
Stockholders' Equity Attributable to Parent	(524,036,297)				(524,036,297)	(487,056,183)
Cash and Cash Equivalents, at Carrying Value	574,111				574,111	1,609,297	$ 1,238,030		$ 11,195,412
Restricted Cash and Cash Equivalents, Current	$ 3,000,000				$ 3,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	278,735,799				278,735,799
Line of Credit, Current	$ 6,960,340				$ 6,960,340	$ 6,368,793
Preferred Stock, Redemption Amount	512,100,000				512,100,000
Debt, Long-term and Short-term, Combined Amount	$ 35,800,000				35,800,000
Loss Contingency, Damages Sought, Value					$ 25,000,000

Note 4 - Detail of Certain Ba32

Note 4 - Detail of Certain Balance Sheet Accounts (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Inventory Write Down	$ 4,700,000		$ 4,700,000		$ 7,900,000
Depreciation	454,000	$ 599,000	1,400,000	$ 2,600,000
Amortization of Intangible Assets	$ 21,000	$ 17,000	$ 62,000	$ 46,000

Note 4 - Detail of Certain Ba33

Note 4 - Detail of Certain Balance Sheet Accounts - Summary of Intangible Assets (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Technology and Intellectual Property [Member] | Minimum [Member]
Estimated Remaining Useful Life	328 days	2 years 255 days
Technology and Intellectual Property [Member] | Maximum [Member]
Estimated Remaining Useful Life	20 years	20 years
Technology and Intellectual Property [Member]
Cost, Less Impairment Charges	$ 3,091,026	$ 2,796,580
Accumulated Amortization	(285,651)	(224,101)
Net Book Value	2,805,375	2,572,479
Net Book Value	$ 2,805,375	$ 2,572,479

Note 5 - Debt Issuance Costs (D

Note 5 - Debt Issuance Costs (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Other Current Assets [Member]
Deferred Finance Costs, Current, Net	$ 1,600,000		$ 1,600,000
First Capital and Medley [Member]
Debt Issuance Cost			6,000,000
Pegasus Guaranty [Member]
Debt Issuance Cost			2,800,000
Amortization of Financing Costs	$ 398,000	$ 312,000	$ 1,131,106	$ 1,299,931

Note 6 - Lines of Credit and 35

Note 6 - Lines of Credit and Note Payable (Details Textual) - USD ($)	Sep. 11, 2015	Feb. 19, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Apr. 25, 2014
Medley Capital Corporation [Member] | Medley Term Loan [Member] | Commitment Fees [Member] | Medley Warrant [Member]
Accretion of Discount			$ 195,000	$ 195,000	$ 584,000	$ 474,000
Debt Instrument, Increase, Accrued Interest			$ 160,000	$ 157,000	$ 474,000	382,000
Medley Capital Corporation [Member] | Medley Term Loan [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate		12.00%
Medley Capital Corporation [Member] | Medley Term Loan [Member]
Debt Instrument, Interest Rate, Effective Percentage			12.33%		12.33%
Notes Payable		$ 30,500,000
Restricted Cash and Cash Equivalents, Current		3,000,000
First Capital [Member] | Accounts Receivable [Member]
Debt Instrument, Collateral Amount			$ 6,600,000		$ 6,600,000
First Capital [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	5.50%				5.50%
First Capital [Member]
Line of Credit Facility, Maximum Borrowing Capacity								$ 22,500,000
Line of Credit Facility, Remaining Borrowing Capacity			9,100,000		$ 9,100,000
Debt Instrument, Collateral Amount			6,600,000		6,600,000		$ 5,400,000
Line of Credit Facility, Eligible Collateral Inventory			$ 10		$ 10
Debt Instrument, Interest Rate, Effective Percentage			5.70%		5.70%
Change in Interest Margin Payable	1.50%
Medley Term Loan [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 30,500,000
Amendment to Medley Term Loan [Member]
Term Loan Covenants, Cash Proceeds from Offering to be Used in EBITDA Calcuation	$ 10,000,000
Accretion of Discount					$ 584,304	473,935
Restricted Cash and Cash Equivalents, Current			$ 3,000,000		3,000,000
Debt Instrument, Increase, Accrued Interest					$ (473,955)	$ (381,611)

Note 6 - Lines of Credit and 36

Note 6 - Lines of Credit and Note Payable - Lines of Credit and Note Payable (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
First Capital [Member]
FCC ABL, revolving line of credit	$ 6,960,340	$ 6,368,793
Medley Term Loan [Member]
Medley Term Loan	28,871,320	27,813,061
FCC ABL, revolving line of credit	6,960,340	6,368,793
Medley Term Loan	28,871,320	27,813,061
	$ 35,831,660	$ 34,181,854

Note 7 - Fair Value Measureme37

Note 7 - Fair Value Measurements - Financial Assets and Liabilities Accounted For at Fair Value on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member]	Sep. 30, 2015USD ($)
Fair Value, Inputs, Level 1 [Member] | Pegasus Commitment [Member]
Pegasus Commitment
Fair Value, Inputs, Level 1 [Member] | Riverwood Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 1 [Member] | September Two Thousand Twelve Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 1 [Member] | Pegasus Warrant [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 1 [Member] | THD Warrant [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 1 [Member] | Medley Warrant [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 1 [Member] | Pegasus Guaranty Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 1 [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 2 [Member] | Pegasus Commitment [Member]
Pegasus Commitment
Fair Value, Inputs, Level 2 [Member] | Riverwood Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 2 [Member] | September Two Thousand Twelve Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 2 [Member] | Pegasus Warrant [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 2 [Member] | THD Warrant [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 2 [Member] | Medley Warrant [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 2 [Member] | Pegasus Guaranty Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 2 [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 3 [Member] | Pegasus Commitment [Member]
Pegasus Commitment	$ 286,400
Fair Value, Inputs, Level 3 [Member] | Riverwood Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring	2,817,004
Fair Value, Inputs, Level 3 [Member] | September Two Thousand Twelve Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring	286,400
Fair Value, Inputs, Level 3 [Member] | Pegasus Warrant [Member]
Liabilities, Fair Value Disclosure, Recurring	1,557,000
Fair Value, Inputs, Level 3 [Member] | THD Warrant [Member]
Liabilities, Fair Value Disclosure, Recurring	120,082
Fair Value, Inputs, Level 3 [Member] | Medley Warrant [Member]
Liabilities, Fair Value Disclosure, Recurring	896,354
Fair Value, Inputs, Level 3 [Member] | Pegasus Guaranty Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring	1,026,214
Fair Value, Inputs, Level 3 [Member]
Liabilities, Fair Value Disclosure, Recurring	$ 6,703,054

Note 7 - Fair Value Measureme38

Note 7 - Fair Value Measurements - Reconciliation of Beginning and Ending Balances for Assets and Liabilities Accounted For at Fair Value on a Recurring Basis (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Pegasus Commitment [Member]
Beginning balance	$ 720,000	$ 1,407,335
Realized and unrealized gains included in net loss	$ (433,600)	$ (367,335)
Purchases, sales, issuances and settlements
Transfers in or out of Level 3
Ending balance	$ 286,400	$ 1,040,000
Riverwood Warrants [Member]
Beginning balance	(2,352,027)	(5,002,664)
Realized and unrealized gains included in net loss	$ (464,977)	$ 1,746,011
Purchases, sales, issuances and settlements
Transfers in or out of Level 3
Ending balance	$ (2,817,004)	$ (3,256,653)
September Two Thousand Twelve Warrants [Member]
Beginning balance	(720,000)	(1,407,335)
Realized and unrealized gains included in net loss	$ 433,600	$ 367,335
Purchases, sales, issuances and settlements
Transfers in or out of Level 3
Ending balance	$ (286,400)	$ (1,040,000)
Pegasus Warrant [Member]
Beginning balance	(1,300,000)	(2,765,047)
Realized and unrealized gains included in net loss	$ (257,000)	$ 965,047
Purchases, sales, issuances and settlements
Transfers in or out of Level 3
Ending balance	$ (1,557,000)	$ (1,800,000)
THD Warrant [Member]
Beginning balance	(43,928)
Realized and unrealized gains included in net loss	$ (76,154)	$ (39,867)
Purchases, sales, issuances and settlements
Transfers in or out of Level 3		$ (74,576)
Ending balance	$ (120,082)	$ (114,443)
Medley Warrant [Member]
Beginning balance	(577,065)
Realized and unrealized gains included in net loss	$ (319,289)	$ 1,847,049
Purchases, sales, issuances and settlements		$ (3,170,361)
Transfers in or out of Level 3
Ending balance	$ (896,354)	$ (1,323,312)
Series J Warrants [Member]
Beginning balance
Realized and unrealized gains included in net loss		$ (25,140,561)
Purchases, sales, issuances and settlements		(12,505,739)
Transfers in or out of Level 3		$ 37,646,300
Ending balance
Pegasus Guaranty Warrants [Member]
Beginning balance	(643,924)
Realized and unrealized gains included in net loss	$ (382,290)	$ 1,901,193
Purchases, sales, issuances and settlements		$ (3,336,574)
Transfers in or out of Level 3
Ending balance	$ (1,026,214)	$ (1,435,381)
Beginning balance	(4,916,944)	(7,767,711)
Realized and unrealized gains included in net loss	$ (1,499,710)	(18,721,128)
Purchases, sales, issuances and settlements		(19,012,674)
Transfers in or out of Level 3		37,571,724
Ending balance	$ (6,416,654)	$ (7,929,789)

Note 8 - Stockholders' Equity39

Note 8 - Stockholders' Equity (Details Textual)	Jun. 12, 2014	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)
Restricted Stock [Member] | Director [Member]
Allocated Share-based Compensation Expense		$ 128,000	$ 221,000	$ 258,000	$ 412,000
Restricted Stock [Member] | Scientific Advisory Board [Member]
Allocated Share-based Compensation Expense		$ 0	$ 26,000	37,000	31,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Recipients	5
Allocated Share-based Compensation Expense				$ 257,842	$ 412,451

Note 8 - Stockholders' Equity -

Note 8 - Stockholders' Equity - Warrants Outstanding for Purchase of Common Stock (Details)	Sep. 30, 2015$ / sharesshares
Investors in Rights Offering [Member] | Series D Warrants [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.95
Investors in Rights Offering [Member] | Series D Warrants [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.96
Investors in Rights Offering [Member] | Series D Warrants [Member]
Number of Common Shares (in shares) | shares	1,192,048
The Home Depot [Member] | Purchasing Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.95
Number of Common Shares (in shares) | shares	8,456,432
Riverwood Warrants [Member] | RW LSG Management Holdings LLC [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights
Number of Common Shares (in shares) | shares	12,664,760
Riverwood Warrants [Member] | Certain Other Investors [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights
Number of Common Shares (in shares) | shares	5,427,751
September Two Thousand Twelve Warrants [Member] | Cleantech A [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.72
Number of Common Shares (in shares) | shares	3,406,041
September Two Thousand Twelve Warrants [Member] | Cleantech B [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.72
Number of Common Shares (in shares) | shares	593,959
September Two Thousand Twelve Warrants [Member] | Portman [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.72
Number of Common Shares (in shares) | shares	4,000,000
Private Placement Series H [Member] | Acquillian Investments LLC [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.18
Number of Common Shares (in shares) | shares	830,508
Pegasus Warrant [Member] | Pegasus Capital [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights
Number of Common Shares (in shares) | shares	10,000,000
Series J Warrants [Member] | Investors in Series J Follow on Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.001
Number of Common Shares (in shares) | shares	212,164,300
Series J Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.001
Medley Warrant [Member] | Medley Capital Corporation [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.95
Number of Common Shares (in shares) | shares	10,000,000
Pegasus Guaranty Warrants [Member] | Pegasus Capital [Member]
Number of Common Shares (in shares) | shares	10,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights
Number of Common Shares (in shares) | shares	278,735,799

Note 9 - Earnings (Loss) Per 41

Note 9 - Earnings (Loss) Per Share (Details Textual) - $ / shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 11, 2015	Jan. 30, 2015
Series J Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.001		$ 0.001		$ 0.001	$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	213.3	177.1	209.8	190.4

Note 9 - Earnings (Loss) Per 42

Note 9 - Earnings (Loss) Per Share - Computation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Controlling Shareholders [Member] | Series J Preferred Stock [Member]
Deemed dividends related to the Series J Preferred Stock attributable to all shareholders	$ (11,742,251)	$ (9,571,504)	$ (23,178,283)	$ (34,077,591)
Controlling Shareholders [Member]
Net loss attributable to common stock	203,149	(1,686,077)	(11,841,266)	(43,394,934)
Undistributed net loss	$ (11,539,102)	$ (11,257,581)	$ (35,019,549)	$ (76,901,951)
Basic and diluted weighted average number of common shares outstanding (in shares)	303,817,578	255,194,735	296,699,120	220,629,709
Basic and diluted net loss per weighted average common share (in dollars per share)	$ (0.04)	$ (0.04)	$ (0.12)	$ (0.35)
Noncontrolling Shareholders [Member] | Series J Preferred Stock [Member]
Deemed dividends related to the Series J Preferred Stock attributable to all shareholders	$ (3,826,160)	$ (2,364,374)	$ (7,702,028)	$ (8,190,666)
Noncontrolling Shareholders [Member]
Net loss attributable to common stock	66,195	(416,499)	(3,934,793)	(10,430,121)
Undistributed net loss	$ (3,759,965)	$ (2,780,873)	$ (11,636,821)	$ (19,191,361)
Basic and diluted weighted average number of common shares outstanding (in shares)	98,997,606	63,038,781	98,591,636	53,029,108
Basic and diluted net loss per weighted average common share (in dollars per share)	$ (0.04)	$ (0.04)	$ (0.12)	$ (0.36)
Net loss attributable to common stock	$ 283,787	$ (2,102,576)	$ (15,761,616)	$ (53,825,055)

Note 9 - Earnings (Loss) Per 43

Note 9 - Earnings (Loss) Per Share - Computation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Controlling Shareholders [Member] | Series J Preferred Stock [Member]
Deemed dividends related to the Series J Preferred Stock attributable to all shareholders	$ (23,178,283)	$ (34,077,591)
Controlling Shareholders [Member]
Net loss attributable to common stock	$ (11,841,266)	(43,394,934)
Deemed dividends due to the issuance of Pegasus Guaranty Warrants as compensation for guaranty provided by controlling shareholders		570,574
Undistributed net loss	$ (35,019,549)	$ (76,901,951)
Basic and diluted weighted average number of common shares outstanding (in shares)	296,699,120	220,629,709
Basic and diluted net loss per weighted average common share (in dollars per share)	$ (0.12)	$ (0.35)
Noncontrolling Shareholders [Member] | Series J Preferred Stock [Member]
Deemed dividends related to the Series J Preferred Stock attributable to all shareholders	$ (7,702,028)	$ (8,190,666)
Noncontrolling Shareholders [Member]
Net loss attributable to common stock	$ (3,934,793)	(10,430,121)
Deemed dividends due to the issuance of Pegasus Guaranty Warrants as compensation for guaranty provided by controlling shareholders		(570,574)
Undistributed net loss	$ (11,636,821)	$ (19,191,361)
Basic and diluted weighted average number of common shares outstanding (in shares)	98,591,636	53,029,108
Basic and diluted net loss per weighted average common share (in dollars per share)	$ (0.12)	$ (0.36)
Net loss attributable to common stock	$ (15,761,616)	$ (53,825,055)

Note 10 - Related Party Trans44

Note 10 - Related Party Transactions (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 11, 2015	Jan. 30, 2015
Holdings III [Member ] | Series J Redeemable Convertible Preferred Stock [Member]
Shares Issued, Price Per Share		$ 1,000	$ 1,000
Preferred Units, Issued		10,000	11,525
Proceeds from Other Equity	$ 21.50
Pegasus Capital [Member]
Ownership Percentage of Subsidiary Held in Parent	90.00%

Note 11 - Restructuring Expen45

Note 11 - Restructuring Expense (Details Textual)	Sep. 30, 2015USD ($)
Facility Closing [Member]
Restructuring and Related Cost, Expected Cost	$ 200,000
Restructuring and Related Cost, Expected Cost Remaining	$ 504,000

Note 11 - Restructuring Expen46

Note 11 - Restructuring Expense - Restructuring Expense and Related Charges (Details) - USD ($)		9 Months Ended
		Sep. 30, 2015	Sep. 30, 2014
Facility Closing [Member]
Charges		$ 297,770	$ 2,558,072	[1]
Organization Optimization Initiative [Member]
Charges	[2]		114,278
Charges		$ 297,770	$ 2,672,350
[1]	These charges relate to a significant cost reduction plan initiated during the fourth quarter of 2013 that includes moving the majority of the Company's manufacturing to its contract manufacturers in Asia, related workforce reductions in Satellite Beach, Florida and cost reductions in our foreign subsidiaries. The Company estimates it will incur $200,000 in additional expenses throughout this cost reduction plan, primarily related to additional headcount reductions. These additional costs are expected to be incurred during 2015.
[2]	In September 2011, the Company began implementing a restructuring plan designed to further increase efficiencies across the organization and lower the overall cost structure. In 2012, the Company extended the restructuring plan to further increase efficiencies across the organization and lower its overall cost structure. The plan included a significant reduction in full time headcount and the closing of the Company's offices in the United Kingdom and Australia. For the nine months ended September 30, 2014, these expenses related to the final liquidation of the Australian entity.

Note 11 - Restructuring Expen47

Note 11 - Restructuring Expense - Accrued Liability Associated with Restructuring Charges (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Facility Closing [Member]
Accrued liability		$ 959,240
Charges		297,770
Payments		(1,162,030)
Accrued liability	$ 94,980	94,980
Excess Facilities [Member]
Accrued liability		$ 353,269
Charges
Payments		$ (82,247)
Accrued liability	271,022	271,022
Other Exit Costs [Member]
Accrued liability		$ 138,840
Charges
Payments		$ (1,013)
Accrued liability	$ 137,827	137,827
Accrued liability		1,451,349
Charges		297,770
Payments		(1,245,290)
Accrued liability	$ 503,829	$ 503,829

Note 12 - Concentrations of C48

Note 12 - Concentrations of Credit Risk (Details Textual) - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Sales Revenue, Net [Member]
Concentration Risk, Percentage	89.00%	82.00%	88.00%	78.00%
Accounts Receivable [Member]
Concentration Risk, Percentage			78.00%		77.00%

Note 13 - Commitments and Con49

Note 13 - Commitments and Contingencies (Details Textual)	9 Months Ended
	Sep. 30, 2015USD ($)
Geveran Case [Member]
Loss Contingency, Damages Sought, Value	$ 25,000,000
Loss Contingency, Damages Sought, Value	$ 25,000,000